Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US

被引：0

作者：

Cohen, Joshua M. ^{[1
]}

Thompson, Stephen ^{[1
]}

Patterson-Lomba, Oscar ^{[2
]}

Driessen, Maurice ^{[3
]}

Seminerio, Michael ^{[1
]}

Carr, Karen ^{[1
]}

Mu, Fan ^{[2
]}

机构：

[1] Teva Branded Pharmaceut Prod R&D Inc, Petah Tiqwa, Israel

[2] Anal Grp, Boston, MA USA

[3] Teva Pharmaceut, Petah Tiqwa, Israel

来源：

NEUROLOGY | 2021年 / 96卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

4171

引用

页数：3

共 50 条

[1] Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany
Heinze, A.
Totev, T.
Krasenbaum, L.
Terasawa, E.
Akcicek, H.
Hipp, J.
Sun, R.
Yim, E.
Driessen, M.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 419 - 419
[2] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS WITH QUARTERLY AND MONTHLY FREMANEZUMAB IN ADULT PATIENTS WITH MIGRAINE IN A US REAL-WORLD SETTING
Cohen, J.
Thompson, S.
Ayyagari, R.
Driessen, M.
Seminerio, M.
Carr, K.
Yim, E.
[J]. VALUE IN HEALTH, 2022, 25 (01) : S36 - S36
[3] Real-world data on reductions in migraine and headache days with fremanezumab treatment for US patients with chronic and episodic migraine: Results from a physician chart review study
Cohen, J. M.
Thompson, S. F.
Patterson-Lomba, O.
Driessen, M. T.
Seminerio, M. J.
Carr, K.
Mu, F.
[J]. HEADACHE, 2021, 61 : 70 - 71
[4] Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway
Driessen, M. T.
Patterson-Lomba, O.
Mu, F.
Thompson, S. F.
Seminerio, M. J.
Carr, K.
Sun, R.
Totev, T.
Yim, E.
Ayyagari, R.
Cohen, J. M.
[J]. HEADACHE, 2021, 61 : 141 - 141
[5] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Driessen, Maurice T.
Cohen, Joshua M.
Thompson, Stephen F.
Patterson-Lomba, Oscar
Seminerio, Michael J.
Carr, Karen
Totev, Todor, I
Sun, Rochelle
Yim, Erica
Mu, Fan
Ayyagari, Rajeev
[J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
[6] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
Maurice T. Driessen
Joshua M. Cohen
Stephen F. Thompson
Oscar Patterson-Lomba
Michael J. Seminerio
Karen Carr
Todor I. Totev
Rochelle Sun
Erica Yim
Fan Mu
Rajeev Ayyagari
[J]. The Journal of Headache and Pain, 2022, 23
[7] US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine
Cohen, Joshua M.
Thompson, Stephen
Ayyagari, Rajeev
Driessen, Maurice
Seminerio, Michael
Carr, Karen
Yim, Erica
[J]. NEUROLOGY, 2021, 96 (15)
[8] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS AFTER INITIATING FREMANEZUMAB FOR PATIENTS WITH MIGRAINE AND PRIOR USE OF ANOTHER MONOCLONAL ANTIBODY TARGETING THE CGRP PATHWAY IN A US REAL-WORLD SETTING
Driessen, M.
Patterson-Lomba, O.
Mu, F.
Thompson, S.
Seminerio, M.
Carr, K.
Sun, R.
Totev, T.
Yim, E.
Ayyagari, R.
Cohen, J.
[J]. VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
[9] Real-world Reductions in Migraine-related Healthcare Resource Utilization for German Patients Initiating Fremanezumab
Heinze, A.
Totev, T.
Krasenbaum, L.
Terasawa, E.
Akcicek, H.
Hipp, J.
Sun, R.
Yilma, B.
Driessen, M.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 420 - 420
[10] Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
Afridi, S.
Totev, T.
Krasenbaum, L. J.
Terasawa, E.
Akcicek, H.
Dhiraj, D.
Sun, R.
Yilma, B.
Driessen, M. T.
[J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):

← 1 2 3 4 5 →